Aileron Therapeutics (ALRN) Competitors $2.76 -0.06 (-2.13%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ALRN vs. PDSB, PULM, UBX, CPIX, ACB, TRVI, BMEA, TCRX, STRO, and MOLNShould you be buying Aileron Therapeutics stock or one of its competitors? The main competitors of Aileron Therapeutics include PDS Biotechnology (PDSB), Pulmatrix (PULM), Unity Biotechnology (UBX), Cumberland Pharmaceuticals (CPIX), Aurora Cannabis (ACB), Trevi Therapeutics (TRVI), Biomea Fusion (BMEA), TScan Therapeutics (TCRX), Sutro Biopharma (STRO), and Molecular Partners (MOLN). These companies are all part of the "medical" sector. Aileron Therapeutics vs. PDS Biotechnology Pulmatrix Unity Biotechnology Cumberland Pharmaceuticals Aurora Cannabis Trevi Therapeutics Biomea Fusion TScan Therapeutics Sutro Biopharma Molecular Partners PDS Biotechnology (NASDAQ:PDSB) and Aileron Therapeutics (NASDAQ:ALRN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings. Does the media favor PDSB or ALRN? In the previous week, PDS Biotechnology had 2 more articles in the media than Aileron Therapeutics. MarketBeat recorded 9 mentions for PDS Biotechnology and 7 mentions for Aileron Therapeutics. Aileron Therapeutics' average media sentiment score of 0.80 beat PDS Biotechnology's score of 0.55 indicating that Aileron Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PDS Biotechnology 1 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aileron Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in PDSB or ALRN? 26.8% of PDS Biotechnology shares are held by institutional investors. Comparatively, 90.9% of Aileron Therapeutics shares are held by institutional investors. 9.5% of PDS Biotechnology shares are held by company insiders. Comparatively, 5.1% of Aileron Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community favor PDSB or ALRN? Aileron Therapeutics received 144 more outperform votes than PDS Biotechnology when rated by MarketBeat users. However, 69.00% of users gave PDS Biotechnology an outperform vote while only 66.98% of users gave Aileron Therapeutics an outperform vote. CompanyUnderperformOutperformPDS BiotechnologyOutperform Votes6969.00% Underperform Votes3131.00% Aileron TherapeuticsOutperform Votes21366.98% Underperform Votes10533.02% Which has higher earnings and valuation, PDSB or ALRN? PDS Biotechnology is trading at a lower price-to-earnings ratio than Aileron Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPDS BiotechnologyN/AN/A-$42.94M-$1.16-1.75Aileron TherapeuticsN/AN/A-$15.73M-$3.12-0.88 Is PDSB or ALRN more profitable? Aileron Therapeutics' return on equity of -74.08% beat PDS Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets PDS BiotechnologyN/A -139.57% -67.22% Aileron Therapeutics N/A -74.08%-27.93% Which has more volatility & risk, PDSB or ALRN? PDS Biotechnology has a beta of 1.93, meaning that its stock price is 93% more volatile than the S&P 500. Comparatively, Aileron Therapeutics has a beta of 2.35, meaning that its stock price is 135% more volatile than the S&P 500. Do analysts rate PDSB or ALRN? PDS Biotechnology presently has a consensus price target of $12.33, suggesting a potential upside of 509.05%. Aileron Therapeutics has a consensus price target of $19.00, suggesting a potential upside of 588.41%. Given Aileron Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aileron Therapeutics is more favorable than PDS Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PDS Biotechnology 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Aileron Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 SummaryAileron Therapeutics beats PDS Biotechnology on 10 of the 15 factors compared between the two stocks. Ad Wide Moat ResearchTrump said you could learn something from this manEarly Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement. Here’s everything you need to know. Get Aileron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALRN vs. The Competition Export to ExcelMetricAileron TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$59.81M$6.44B$5.05B$8.82BDividend YieldN/A8.11%5.17%4.07%P/E Ratio-0.8810.69125.6917.78Price / SalesN/A243.731,179.7874.25Price / CashN/A22.1633.7732.53Price / Book1.965.474.684.68Net Income-$15.73M$153.61M$119.54M$226.08M7 Day Performance-22.69%-4.32%-2.46%-2.04%1 Month Performance-23.76%-8.61%-4.08%0.06%1 Year Performance46.03%28.79%29.82%24.60% Aileron Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALRNAileron Therapeutics3.5661 of 5 stars$2.76-2.1%$19.00+588.4%+46.0%$59.81MN/A-0.889PDSBPDS Biotechnology1.825 of 5 stars$2.03-3.3%$12.33+509.1%-67.9%$78.37MN/A0.0020PULMPulmatrix0.2627 of 5 stars$5.62+3.5%N/A+210.5%$19.83M$7.30M0.0020Analyst ForecastUBXUnity Biotechnology3.6059 of 5 stars$1.17+0.9%$8.00+583.8%-42.1%$19.55M$240,000.000.0060CPIXCumberland Pharmaceuticals0.7205 of 5 stars$1.12+0.9%N/A-34.9%$15.59M$39.55M0.0080Analyst ForecastACBAurora Cannabis0.6391 of 5 stars$4.24+1.4%N/A-11.0%$232.52M$200.35M-5.581,073TRVITrevi Therapeutics3.4144 of 5 stars$2.77-7.7%$7.43+168.2%+113.1%$230.60MN/A0.0020BMEABiomea Fusion3.4346 of 5 stars$6.28-2.2%$30.50+385.7%-39.1%$227.58MN/A-1.5750TCRXTScan Therapeutics2.6162 of 5 stars$4.12-2.1%$12.00+191.3%-10.6%$223.02M$21.05M0.00100STROSutro Biopharma4.5351 of 5 stars$2.67-1.1%$12.14+354.8%-3.6%$222.64M$153.73M0.00240Analyst ForecastAnalyst RevisionMOLNMolecular Partners0.389 of 5 stars$5.20-4.8%$4.50-13.5%+19.8%$220.24M$7.84M0.00180 Related Companies and Tools Related Companies PDS Biotechnology Alternatives Pulmatrix Alternatives Unity Biotechnology Alternatives Cumberland Pharmaceuticals Alternatives Aurora Cannabis Alternatives Trevi Therapeutics Alternatives Biomea Fusion Alternatives TScan Therapeutics Alternatives Sutro Biopharma Alternatives Molecular Partners Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALRN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands...Angel Publishing | SponsoredJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purpose...Priority Gold | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredTrump said you could learn something from this manEarly Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide vic...Wide Moat Research | SponsoredThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of ...WealthPress | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aileron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aileron Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
